Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_assertion type Assertion NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_head.
- NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_assertion description "[The efficacy of LPZ (15 mg/day) as maintenance therapy for erosive RE is influenced by CYP2C19 polymorphism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_provenance.
- NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_assertion evidence source_evidence_literature NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_provenance.
- NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_assertion SIO_000772 17295875 NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_provenance.
- NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_assertion wasDerivedFrom befree-20140225 NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_provenance.
- NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_assertion wasGeneratedBy ECO_0000203 NP406553.RAc2iq0clFMRzQlCcWsmz6wQxTcGhemFi0doV9nACv4W8130_provenance.